Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Patriarca

Showing results (81-90 of 156) with videos related to

Pageof 16
Sort By:
Expert Opinion on Biological Therapy|May 17, 2017
New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?Francesca Patriarca, Luisa Giaccone, Francesco Onida, et al.
Blood|January 14, 2011
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patientsFrancesca Gay, Alessandra Larocca, Pierre Wijermans, et al.
Blood|April 15, 2011
Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myelomaLuisa Giaccone, Barry Storer, Francesca Patriarca, et al.
Haematologica|June 22, 2019
Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugsVittorio Montefusco, Francesca Gay, Stefano Spada, et al.
Oncotarget|October 26, 2016
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysisStefania Oliva, Manuela Gambella, Milena Gilestro, et al.
The Lancet. Haematology|January 6, 2024
Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow TransplantationOlaf Penack, Monia Marchetti, Mahmoud Aljurf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2010
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trialAntonio Palumbo, Sara Bringhen, Davide Rossi, et al.
Oncotarget|November 18, 2015
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)Carolina Terragna, Daniel Remondini, Marina Martello, et al.
Blood|March 19, 2021
Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myelomaAlessandra Larocca, Francesca Bonello, Gianluca Gaidano, et al.
Blood|December 10, 2008
Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di MidolloBenedetto Bruno, Marcello Rotta, Francesca Patriarca, et al.
Pageof 16

Showing results (81-90 of 156) with videos related to

Sort By:
Pageof 16
Expert Opinion on Biological Therapy|May 17, 2017
New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?Francesca Patriarca, Luisa Giaccone, Francesco Onida, et al.
Blood|January 14, 2011
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patientsFrancesca Gay, Alessandra Larocca, Pierre Wijermans, et al.
Blood|April 15, 2011
Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myelomaLuisa Giaccone, Barry Storer, Francesca Patriarca, et al.
Haematologica|June 22, 2019
Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugsVittorio Montefusco, Francesca Gay, Stefano Spada, et al.
Oncotarget|October 26, 2016
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysisStefania Oliva, Manuela Gambella, Milena Gilestro, et al.
The Lancet. Haematology|January 6, 2024
Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow TransplantationOlaf Penack, Monia Marchetti, Mahmoud Aljurf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2010
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trialAntonio Palumbo, Sara Bringhen, Davide Rossi, et al.
Oncotarget|November 18, 2015
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)Carolina Terragna, Daniel Remondini, Marina Martello, et al.
Blood|March 19, 2021
Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myelomaAlessandra Larocca, Francesca Bonello, Gianluca Gaidano, et al.
Blood|December 10, 2008
Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di MidolloBenedetto Bruno, Marcello Rotta, Francesca Patriarca, et al.
Pageof 16